Pfizer's Elrexfio Shows Long-Term OS, But Convenience Counts Too
The drug maker presented data from the pivotal Phase II trial at EHA showing median OS of more than two years for Elrexfio.
The drug maker presented data from the pivotal Phase II trial at EHA showing median OS of more than two years for Elrexfio.